Vireo Health of Rocky Mountain, LLC acquires Medicine Man Technologies, Inc. d/b/a Schwazze for USD 111,000,000 (2026)

Deal facts

Buyer: Vireo Health of Rocky Mountain, LLC
Target: Medicine Man Technologies, Inc. d/b/a Schwazze
Deal value: USD 111,000,000
Announced: 25 March 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: loan-note, deferred

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

19 Mar 2026CompletedClosed
Vireo Health of Rocky Mountain, LLC completes acquisition of Medicine Man Technologies, Inc. d/b/a Schwazze
Item 1.01 Entry into a Material Definitive Agreement . The information under Item 2.01 below related to the LSA (as defined herein), to the extent responsive to Item 1.01, is incorporated by reference herein. Item 2.01 Completion of Acquisition or Disposition of Assets As previously disclosed, in connection with the acquisition of a majority of the outstanding principal amount of 13% Senior Secure
Source

OpinionExit Mode editorial

We see a clear signal in the announced completion of Vireo Health of Rocky Mountain, LLC acquiring Medicine Man Technologies, Inc, trading as Schwazze. This transaction, valued at 111 million USD, is structured as an asset sale rather than a share purchase. For the SME founder reading this, the distinction is vital because asset deals often allow the buyer to cherry-pick specific liabilities while leaving others behind. The consideration mix is equally revealing, relying entirely on loan notes and deferred payments. This structure shifts significant execution risk onto the seller, as the full value is contingent on future performance or the buyer's ability to service the debt.

The sector context adds another layer of complexity. Operating within the US healthcare and cannabis markets, this deal likely navigates a patchwork of state-level regulatory frameworks. While the JSON does not specify the exact jurisdictions, an asset sale in this space frequently triggers change-of-control covenants with landlords, lenders, and state licensing boards. Unlike a share sale where the corporate shell remains intact, an asset transfer requires fresh approvals for each operating licence. The use of deferred consideration suggests the buyer is seeking to align the payout with the successful transfer of these regulatory permissions or the immediate post-close cash flow of the acquired assets.

We think this deal highlights a common trap for founders who focus solely on headline value. A figure of 111 million USD looks impressive on paper, yet the reliance on loan notes means the founder does not hold the cash until specific conditions are met. If the buyer faces liquidity constraints or if regulatory hurdles delay the integration of the assets, the deferred portion may be at risk. The asset sale structure also implies the buyer is not assuming the historical liabilities of Medicine Man Technologies, which can leave the seller exposed to clawbacks if warranties are breached.

Your immediate task this week is to audit your own exit strategy against the mechanics of this deal. Do not accept a headline valuation without mapping exactly how much is cash at completion versus deferred notes, and identify the specific triggers that could delay or reduce that deferred portion. If your target sector involves heavy regulation, ask your legal team to model the cost and timing of transferring every single licence as an asset rather than assuming a share sale will happen automatically.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More asset sale deals More from Vireo Health of Rocky Mountain, LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC to acquire Selectis Health, Inc.

GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC and Selectis Health, Inc. entered the Exit Mode archive.

Buyer: GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC
Target: Selectis Health, Inc.
Deal value: USD 15,700,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

15 April 2026CompletedHealthcare

MeiraGTx Holdings plc to acquire Janssen Pharmaceuticals, Inc.

MeiraGTx Holdings plc and Janssen Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: MeiraGTx Holdings plc
Target: Janssen Pharmaceuticals, Inc.
Deal value: USD 25,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

7 April 2026Firm intentionHealthcare

Supernus Pharmaceuticals, Inc. to acquire Navitor Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. and Navitor Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Supernus Pharmaceuticals, Inc.
Target: Navitor Pharmaceuticals, Inc.
Deal value: USD 350,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

30 March 2026Firm intentionHealthcare

SCYNEXIS, Inc. to acquire Poxel SA

SCYNEXIS, Inc. and Poxel SA entered the Exit Mode archive.

Buyer: SCYNEXIS, Inc.
Target: Poxel SA
Deal value: USD 8,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals France deals

2 January 2026CompletedHealthcare

Sunstring Ltd to acquire A.M.S 2000 Trading Impex SRL

Sunstring Ltd has agreed to acquire the assets of A.M.S 2000 Trading Impex SRL, a diagnostics distributor based in Israel, in a transaction structured as an asset sale.…

Buyer: Sunstring Ltd
Target: A.M.S 2000 Trading Impex SRL
Deal value: Not disclosed
Deal type: asset sale

Read deal Healthcare deals asset sale deals Israel deals

Buyer history